Search Results

Fosun Pharma USA Inc. (“Fosun Pharma USA”) is pleased to announce that Chief Executive Officer, Rong Yang, and several Fosun Pharma USA executives, will be attending the 42nd Annual J.P. Morgan Healthcare Conference (JPM ’24), taking place in San Francisco, California, Jan. 8 - 11, 2024.

Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical stage assets, further solidifying the relationship between the two companies.

Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC).

Shanghai Fosun Pharmaceutical Co., Ltd.* announced its 2023 Interim Results for the first half of 2023.

The Japan-based Global Health Innovative Technology Fund announced that it will invest approximately US$3.3 million in a global multicenter Phase III clinical trial project led by Fosun Pharma for a triple artemisinin combination drug against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

World Malaria Day is marked each year on April 25. World Health Organization gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world.

Palatin Technologies, Inc. today announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China.